Logo twitter-512

Diagnostic Medical Imaging

Pediatric Oncology & Hematology

The Paediatric Oncology & Haematology Department will strive to establish itself as one of the region's strongest translational research teams with a specific focus both on leukaemia & lymphoma and on cancers in children.

 

The Paediatric Oncology and Haematology Department aims to optimise current treatments and develop and advance novel therapies in patients with leukaemia or lymphoma and children with cancer.

 

Although there are similarities between paediatric and adult leukaemia and lymphoma, those in adulthood are often biologically different, can be associated with poor prognosis and represent a particular area of unmet clinical need.

 

Our vision

Optimise delivery and individualise therapy according to host and disease characteristics:

 

Molecular classification of disease (prognostic and predictive biomarkers)

Learn how chemotherapeutic approaches can be optimised through an improved knowledge of drug disposition and metabolism in paediatric patient populations

Develop novel treatments for patients with leukaemia/lymphoma and children with cancer:

 

Identify novel targets, undertake pre-clinical drug development and advance promising new therapies to early clinical trials.

 

This department will provide diagnostic services and specialist care for children under 18 years of age with cancer (paediatric oncology), non-malignant blood diseases (paediatric haematology) and blood and marrow stem-cell (haematopoietic) transplantation.

 

The mission of the department will be to achieve and maintain excellence in the areas of clinical care, education and research.

 

Reflecting the size and diversity of its clinical services, the department will be functionally organized into six sections and three programs.  There will be the leukaemia/lymphoma section, the neuro-oncology (brain tumour) section , the solid tumour section, the blood and marrow transplantation section, the haematology section, the inpatient services section, the aftercare (long-term follow up) program, the new agent and innovative therapy program and the cancer genetics program.  

 

The haematology section will have well-defined large programs in paediatric haemostasis, the paediatric haemoglobinopathies and the paediatric marrow failure syndromes.